Focused On-demand Library for Ubiquitin carboxyl-terminal hydrolase 21

Available from Reaxense
Predicted by Alphafold

Focused On-demand Libraries - Reaxense Collaboration

Explore the Potential with AI-Driven Innovation

This comprehensive focused library is produced on demand with state-of-the-art virtual screening and parameter assessment technology driven by Receptor.AI drug discovery platform. This approach outperforms traditional methods and provides higher-quality compounds with superior activity, selectivity and safety.

Our selection of compounds is from a large virtual library of over 60 billion molecules. The production and distribution of these compounds are managed by our partner Reaxense.

Contained in the library are leading modulators, each labelled with 38 ADME-Tox and 32 physicochemical and drug-likeness qualities. In addition, each compound is illustrated with its optimal docking poses, affinity scores, and activity scores, giving a complete picture.

We utilise our cutting-edge, exclusive workflow to develop focused libraries for enzymes.

 Fig. 1. The sreening workflow of Receptor.AI

It includes comprehensive molecular simulations of the catalytic and allosteric binding pockets and the ensemble virtual screening accounting for their conformational mobility. In the case of designing modulators, the structural changes induced by reaction intermediates are taken into account to leverage activity and selectivity.

Our library is unique due to several crucial aspects:

  • Receptor.AI compiles all relevant data on the target protein, such as past experimental results, literature findings, known ligands, and structural data, thereby enhancing the likelihood of focusing on the most significant compounds.
  • By utilizing advanced molecular simulations, the platform is adept at locating potential binding sites, rendering the compounds in the focused library well-suited for unearthing allosteric inhibitors and binders for hidden pockets.
  • The platform is supported by more than 50 highly specialized AI models, all of which have been rigorously tested and validated in diverse drug discovery and research programs. Its design emphasizes efficiency, reliability, and accuracy, crucial for producing focused libraries.
  • Receptor.AI extends beyond just creating focused libraries; it offers a complete spectrum of services and solutions during the preclinical drug discovery phase, with a success-dependent pricing strategy that reduces risk and fosters shared success in the project.







Alternative names:

Deubiquitinating enzyme 21; Ubiquitin thioesterase 21; Ubiquitin-specific-processing protease 21

Alternative UPACC:

Q9UK80; Q59H60; Q5BKT5; Q5VTW9; Q5VTX0; Q9BTV1; Q9HBS2; Q9NYN4


Ubiquitin carboxyl-terminal hydrolase 21, also known as Deubiquitinating enzyme 21, plays a crucial role in histone modification and gene expression regulation. It specifically deubiquitinates histone H2A, facilitating transcriptional activation by enabling histone H3 methylation at Lys-4. Additionally, it stabilizes BAZ2A/TIP5 and removes NEDD8 from conjugates, impacting protein stability and function. This enzyme also serves as a negative regulator of ribosome quality control by deubiquitinating ribosomal proteins, thus modulating protein synthesis.

Therapeutic significance:

Understanding the role of Ubiquitin carboxyl-terminal hydrolase 21 could open doors to potential therapeutic strategies, particularly in diseases where gene expression regulation and protein stability are compromised.

Looking for more information on this library or underlying technology? Fill out the form below and we'll be in touch with all the details you need.
Thank you! Your submission has been received!
Oops! Something went wrong while submitting the form.